RxDoctor Payments Data

Gerardo Moreira

Psychiatry · El Paso, TXNPI 1013935675

Payments from drug & device makers

$4,030in general payments, 2019–2025

Across 237 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Neurocrine Biosciences, Inc.$466
  • Sunovion Pharmaceuticals Inc.$424
  • Teva Pharmaceuticals USA, Inc.$335
  • Alkermes, Inc.$330
  • AbbVie$287
  • plus $799 from 6 others

What the payments were for

  • Food & beverage$3,91397%
  • Education$1173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,030 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$2,325
Medicare patients
13
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole21$62,041
Aripiprazole35$2,229
Bupropion XlBupropion Hcl46$1,004
Oxcarbazepine18$676
Quetiapine Fumarate30$390
Trazodone Hcl19$272
Divalproex Sodium12$181
Haloperidol13$163
Benztropine Mesylate14$163
Hydroxyzine Hcl11$155
Mirtazapine22$151
Risperidone13$134
Olanzapine13$129
Fluoxetine Hcl17$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$132$62,04121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →